Evidence map›Paper›PMID 31935285›Full record

ArticleBlood advances2020

von Willebrand factor binding to myosin assists in coagulation.

Veronica H Flood, Tricia L Slobodianuk, Daniel Keesler, Hannah K Lohmeier, Scot Fahs, Liyun Zhang, Pippa Simpson, Robert R Montgomery

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Fibronectin binding to von Willebrand factor occurs via the A1 domain.Research and practice in thrombosis and haemostasis · 2021
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Veronica H FloodBlood Research Institute, Versiti, Milwaukee, WI.
Tricia L SlobodianukBlood Research Institute, Versiti, Milwaukee, WI.
Daniel KeeslerDivision of Hematology/Oncology and.
Hannah K LohmeierDivision of Hematology/Oncology and.
Scot FahsBlood Research Institute, Versiti, Milwaukee, WI.
Liyun ZhangDivision of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
Pippa SimpsonDivision of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
Robert R MontgomeryBlood Research Institute, Versiti, Milwaukee, WI.
Children's Hospital of Wisconsin · USMedical College of Wisconsin · USPalmetto Hematology Oncology · USVersiti Blood Center of Wisconsin · US

Funding

Zimmerman Program on the Biology of VWDP01HL144457 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2019 to 2023
$13.3M
Molecular Interactions of FVIII and VWFR01HL139847 · NHLBI · VERSITI WISCONSIN, INC. · PI MONTGOMERY, ROBERT R · 2018 to 2021
$2.3M
NHLBI NIH HHS P01 HL144457NHLBI NIH HHS R01 HL139847
6 · The paper itself

Abstract

von Willebrand factor (VWF) binds to platelets and collagen as a means of facilitating coagulation at sites of injury. Recent evidence has shown that myosin can serve as a surface for thrombin generation and binds to activated factor V and factor X. We studied whether VWF can also bind myosin as a means of bringing factor VIII (FVIII) to sites of clot formation. A myosin-binding assay was developed using skeletal muscle myosin to measure VWF binding, and plasma-derived and recombinant VWF containing molecular disruptions at key VWF sites were tested. Competition assays were performed using anti-VWF antibodies. FVIII binding to myosin was measured using a chromogenic FVIII substrate. Thrombin generation was measured using a fluorogenic substrate with and without myosin. Wild-type recombinant VWF and human plasma VWF from healthy controls bound myosin, whereas plasma lacking VWF exhibited no detectable myosin binding. Binding was multimer dependent and blocked by anti-VWF A1 domain antibodies or A1 domain VWF variants. The specific residues involved in myosin binding were similar, but not identical, to those required for collagen IV binding. FVIII did not bind myosin directly, but FVIII activity was detected when VWF and FVIII were bound to myosin. Myosin enhanced thrombin generation in platelet-poor plasma, although no difference was detected with the addition of myosin to platelet-rich plasma. Myosin may help to facilitate delivery of FVIII to sites of injury and indirectly accelerate thrombin generation by providing a surface for VWF binding in the setting of trauma and myosin exposure.

Indexed as

Blood Coagulationvon Willebrand FactorBlood PlateletsHumansMyosinsThrombinMyosinsThrombinvon Willebrand Factor

Identifiers

PMID31935285
PMCPMC6960459
OpenAlexW2980439989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.